Dynavax to Initiate Phase 1 Studies For TLR-9 Agonist For Asthma – Benzinga

Dynavax to Initiate Phase 1 Studies For TLR-9 Agonist For Asthma
Benzinga
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into Phase 1 clinical studies. Development expenses will be fully funded by AstraZeneca under …

and more »